Lactobacillus probiotics for treating functional dyspepsia in children

Ahyani, Tuty; Supriatmo, Supriatmo; Deliana, Melda; Yudiyanto, Ade Rachmat; Sinuhaji, Atan Baas

doi:10.14238/pi56.1.2016.07

Cited by 2 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Treatment with Lacticaseibacillus rhamnosus (formerly Lactobacillus rhamnosus ) and Lactobacillus acidophilus has been shown to alleviate FD symptoms in children. 5 In adults, the administration of probiotic yogurt containing Lactobacillus gasseri OLL2716 (LG21 yogurt) improved the symptoms of postprandial distress. 21 One advantage exerted by the administration of probiotics as a treatment to control FD is the lack of adverse events reported in the available literature.…”

Section: Introductionmentioning

confidence: 99%

“…2 The prevalence of FD, calculated using large population-based studies in adults, ranges from 10% to 30% worldwide, 4 while in children, prevalence varies between 3.5% and 27%. 5 In the USA alone, social and economic costs are estimated to be approximately $18.4 billion/year for adults and $5.79 billion/year for children. 4,6 Functional dyspepsia is a chronic GI disorder defined by upper abdominal symptoms originating from the gastroduodenal region and characterized by the absence of morphological disease on routine investigations, including upper GI endoscopy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of main functional dyspepsia symptoms after probiotic administration in patients receiving conventional pharmacological therapies

et al. 2021

View full text Add to dashboard Cite

Objective Postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) are the two main forms of functional dyspepsia (FD). Probiotics are a promising therapy for FD, but current data remains heterogeneous. This work aims to evaluate a probiotic combination of Lacticaseibacillus rhamnosus LR04 (DSM 16605), Lactiplantibacillus pentosus LPS01 (DSM 21980), Lactiplantibacillus plantarum LP01 (LMG P-21021), and Lactobacillus delbrueckii subsp. delbruekii LDD01 (DMS 22106), alone or together with other pharmacological therapies, for clinical improvement of symptoms associated with FD. Methods Patients with FD were enrolled and divided into two groups: PDS and EPS. Probiotic alone or combined with prokinetics, antacids, or proton-pump-inhibitors were administered for 30 days. A progressive-score scale was used to evaluate symptoms in all patients at the beginning of the trial and at 15 days after the end of treatment. Results A cohort of 2676 patients were enrolled (1 357 with PDS; 1 319 with EPS). All patients showed significant improvements in dyspeptic symptoms following treatment. In patients with PDS, probiotic alone resulted in the lowest prevalence of symptoms following treatment, while patients with EPS showed no clear between-treatment differences. Conclusions Dyspeptic symptoms were reduced following treatment in all patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of main functional dyspepsia symptoms after probiotic administration in patients receiving conventional pharmacological therapies

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Patients' information, the severity of symptoms, and quality of life were recorded in a special form at the baseline, end, and two weeks after the end of the treatment. The daily severity of EPS and PDS in the week before the start and end of the intervention were scored using NRS from 0 (no symptoms) to 10 (the most severe symptoms), and the sufficient response to treatment as the primary outcome was defined as a mean NRS score ≤3 in seven days before the end of the intervention [ 28 ]. Also, symptom severity was assessed using the Gastrointestinal Symptom Rating Scale (GSRS).…”

Section: Methodsmentioning

confidence: 99%

Comparison of a Novel Herbal Medicine and Omeprazole in the Treatment of Functional Dyspepsia: A Randomized Double-Blinded Clinical Trial

Bordbar

Miri

Omidi

et al. 2020

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Background. The Trachyspermum ammi L. (TA), Anethum graveolens L. (AG), and Zataria multiflora Boiss (ZM) herbal oils are among the most used herbal products in traditional medicine as the antiseptic, anesthetic, carminative, and antispasmodic. However, there are no clinical studies to evaluate the efficacy of the herbs mentioned in the treatment of functional dyspepsia (FD). This study was designed to appraise the efficacy and safety of a novel herbal medicine consisting of ZM, AG, and TA essential oils compared to omeprazole in FD treatment. Methods. The present study was a randomized double-blind clinical trial with parallel groups in Iran. Patients in control and intervention arms received omeprazole 20 mg once a day and 250 mg soft-gel capsules containing 180 mg of essential oils of ZM, AG, and TA twice a day for two weeks, respectively. The primary outcome was the sufficient response rate in the postprandial distress syndrome (PDS) and/or epigastric pain syndrome (EPS) at the end of the intervention. Secondary outcomes were the improvement rate in the PDS, EPS, Gastrointestinal Symptom Rating Scale (GSRS), and quality of life scores. Also, safety and tolerability were assessed. Results. The within-group comparison of EPS, PDS, total GSRS, GSRS Pain, and GSRS Dyspepsia scores with that at the end of the treatment indicated a significant reduction in both control and intervention groups ( p < 0.001 ). However, after two weeks of treatment, the herbal medication and omeprazole arms were significantly different in the sufficient response rate based on PDS ( p < 0.01 ) and EPS ( p < 0.05 ) scores (78.3% (18/23) and 73.7% (14/19) in the intervention group vs. 36.4% (8/22) and 40.9% (9/22) in the control group). Also, the mean reduction in EPS ( p < 0.05 ), PDS ( p < 0.01 ), and GSRS ( p < 0.001 ) scores after treatment was significantly higher in the intervention group than control group. Conclusion. Based on the study findings, this herbal medicine can be considered as an appropriate treatment of FD. However, a larger multicenter trial is needed to confirm the results of the trial.

show abstract

Lactobacillus probiotics for treating functional dyspepsia in children

Abstract: Background Functional dyspepsia is a common gastrointestinal

Cited by 2 publications

References 14 publications

Evaluation of main functional dyspepsia symptoms after probiotic administration in patients receiving conventional pharmacological therapies

Evaluation of main functional dyspepsia symptoms after probiotic administration in patients receiving conventional pharmacological therapies

Comparison of a Novel Herbal Medicine and Omeprazole in the Treatment of Functional Dyspepsia: A Randomized Double-Blinded Clinical Trial

Contact Info

Product

Resources

About